Everolimus Inhibits Anti-HLA I Antibody-Mediated Endothelial Cell Signaling, Migration and Proliferation More Potently Than Sirolimus

HLA Class I Antibody-Mediated Endothelial Cell Proliferation via the mTOR Pathway

(2014) P. T. Jindra et al.   JOURNAL OF IMMUNOLOGY

Renal Function at Two Years in Liver Transplant Patients Receiving Everolimus: Results of a Randomized, Multicenter Study

(2013) F. Saliba et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Endothelial RAF1/ERK activation regulates arterial morphogenesis

(2013) Y. Deng et al.   BLOOD

Lymphatic fate determination: Playing RAF with ERK

(2013) Yong Deng et al.   CELL CYCLE

The utilization of sirolimus and the impact on wound-healing complications in obese kidney transplant recipients

(2013) Amanda L. Hulbert et al.   CLINICAL TRANSPLANTATION

MicroRNA-21 mediates the rapamycin-induced suppression of endothelial proliferation and migration

(2013) Chongying Jin et al.   FEBS LETTERS

Endothelial ERK signaling controls lymphatic fate specification

(2013) Yong Deng et al.   JOURNAL OF CLINICAL INVESTIGATION

Treatment with everolimus is associated with a procoagulant state

(2013) Marije C. Baas et al.   THROMBOSIS RESEARCH

HLA class I-mediated stress fiber formation requires ERK1/2 activation in the absence of an increase in intracellular Ca2+ in human aortic endothelial cells

(2012) Mary E. Ziegler et al.   AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY

Effect of early conversion from CNI to sirolimus on outcomes in kidney transplant recipients with allograft dysfunction

(2011) Ernesto Paoletti et al.   JOURNAL OF NEPHROLOGY

Everolimus: A Proliferation Signal Inhibitor with Clinical Applications in Organ Transplantation, Oncology, and Cardiology

(2010) Steven Gabardi et al.   PHARMACOTHERAPY

HLA Class I Molecules Partner with Integrin  4 to Stimulate Endothelial Cell Proliferation and Migration

(2010) X. Zhang et al.   Science Signaling

mTOR Inhibitor RAD001 (Everolimus) Has Antiangiogenic/Vascular Properties Distinct from a VEGFR Tyrosine Kinase Inhibitor

(2009) H. A. Lane et al.   CLINICAL CANCER RESEARCH

MHC class I and integrin ligation induce ERK activation via an mTORC2-dependent pathway

(2008) Peter T. Jindra et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Antiangiogenic Therapy with Mammalian Target of Rapamycin Inhibitor RAD001 (Everolimus) Increases Radiosensitivity in Solid Cancer

(2008) P. C. Manegold et al.   CLINICAL CANCER RESEARCH

Post-transplantation antibody monitoring and HLA antibody epitope identification

(2008) Junchao Cai et al.   CURRENT OPINION IN IMMUNOLOGY

Cytoplasmic and nuclear distribution of the protein complexes mTORC1 and mTORC2: rapamycin triggers dephosphorylation and delocalization of the mTORC2 components rictor and sin1

(2008) M. Rosner et al.   HUMAN MOLECULAR GENETICS